Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Switzerland and US sign drug inspection agreement

21
SHARES

To promote Good Manufacturing Practice, Switzerland and the US have signed a Mutual Recognition Agreement to improve pharmaceutical drug inspection.

Switzerland and US sign Good Manufacturing Practice Mutual Recognition Agreement

A Mutual Recognition Agreement (MRA) relating to pharmaceutical Good Manufacturing Practice (GMP) has been signed between Switzerland and the US.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Under the agreement with the Swiss Confederation (Switzerland), the Swiss Agency for Therapeutic Products (Swissmedic) and the US Food and Drug Administration (FDA) will be able to utilise each other’s GMP inspections of pharmaceutical manufacturing facilities, avoiding the need for duplicate inspections.

The Swiss-US Mutual Recognition Agreement (MRA)

“Once the MRA enters into force, the FDA will be able to rely on the factual findings of Swissmedic experts in many cases, thus avoiding duplicate inspections and allowing the FDA to expand its inspectional reach,” shared Andi Lipstein Fristedt, the FDA Deputy Commissioner for Policy, Legislation, and International Affairs, who signed the agreement on behalf of the FDA.

Interpharma, Switzerland’s research-based pharmaceutical industry association stated the agreement “…will strengthen the resilience of supply chains and therefore improve the security of supply.”

Good Manufacturing Practice for pharmaceutical drugs

According to the European Medicines Agency (EMA), Good Manufacturing Practice (GMP) is the minimum standard that a medicines manufacturer must meet in their production processes.

The FDA already has a MRA in place with the European Union (EU) and one with the UK.

The Food and Drug Administration Safety and Innovation Act, enacted in 2012, permitted the FDA to enter into agreements to recognise drug inspections conducted by foreign regulatory authorities determined to be capable of conducting inspections that meet US requirements.

The FDA’s Office of Global Policy and Strategy has been negotiating the US-Switzerland MRA for several years. Before the MRA enters into force, Swissmedic must determine whether the FDA is capable of conducting inspections that meet Swiss requirements. The FDA must make a similar determination with respect to Swissmedic meeting US requirements.

“In today’s global pharmaceutical market, MRAs offer a way for the FDA to work more efficiently and maximise its resources,” added the FDA’s Deputy Commissioner for Policy, Legislation, and International Affairs.

Economics and risks of FDA’s Quality management maturity rating programme

Share via
Share via